This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Welcome back! I’ve been working from home almost this entire summer because of construction on the Red Line. I hate the MBTA. Boston readers know what I mean.
advertisement
This week: “Muscarinics” are hot and Neurocrine Biosciences is the next biotech with a big study readout. I preview. Also, a few more words on the Cassava Sciences’ soap opera.
STAT+ Exclusive Story
Already have an account? Log in
Get unlimited access to award-winning journalism and exclusive events.